Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
K Miller
J W Moul
M Gleave
K Fizazi
J B Nelson
T Morris
F E Nathan
S McIntosh
K Pemberton
C S Higano
机构：
[1] Charité–Universitätsmedizin Berlin,Department of Urology
[2] Duke Cancer Institute,Division of Urology, Department of Surgery and Duke Prostate Center
[3] Duke University Medical Center,Department of Urology
[4] Vancouver Prostate Center,undefined
[5] University of British Columbia,undefined
[6] Institut Gustave Roussy,undefined
[7] University of Paris Sud,undefined
[8] University of Pittsburgh School of Medicine,undefined
[9] AstraZeneca,undefined
[10] AstraZeneca Pharmaceuticals LP,undefined
[11] Fred Hutchinson Cancer Research Center,undefined
[12] University of Washington School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
zibotentan; ZD4054; non-metastatic; castration-resistant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：187 / 192
页数：5
相关论文
共 50 条
  • [31] Non-metastatic castration-resistant Prostate Cancer Apalutamide delays Metastasis in Patients with MOCRPC
    Ruedesheim, Sabine M.
    VISCERAL MEDICINE, 2019, 35 (02) : 139 - 139
  • [32] New treatments for patients with non-metastatic castration-resistant prostate cancer: A nursing perspective
    Olivier, Kara M.
    Floyd, Rebecca
    Smith, Matthew R.
    Shore, Neal D.
    Sutton, Jennifer
    INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2021, 15 (02) : 47 - 58
  • [33] Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
    Erin L. Tomaszewski
    Pierre Moise
    Robert N. Krupnick
    Jared Downing
    Margaret Meyer
    Shevani Naidoo
    Stefan Holmstrom
    The Patient - Patient-Centered Outcomes Research, 2017, 10 : 567 - 578
  • [34] Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
    Tomaszewski, Erin L.
    Moise, Pierre
    Krupnick, Robert N.
    Downing, Jared
    Meyer, Margaret
    Naidoo, Shevani
    Holmstrom, Stefan
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2017, 10 (05): : 567 - 578
  • [35] CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
    Smith, Matthew Raymond
    Agarwal, Neeraj
    Todenhoefer, Tilman
    Trepiakas, Redas
    Lee, Jae-Lyun
    Lithio, Andrew
    Chapman, Sonya
    Nacerddine, Karim
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer
    Chouaid, Christos
    Nathan, Faith
    Pemberton, Kristine
    Morris, Thomas
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 1203 - 1208
  • [37] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Fizazi, K.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S522 - S522
  • [38] A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer
    Christos Chouaid
    Faith Nathan
    Kristine Pemberton
    Thomas Morris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1203 - 1208
  • [39] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Smith, M. R.
    Shore, N. D.
    Tammela, T. L. J.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1327 - S1328
  • [40] Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide
    Fujmoto, Saizo
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Hamaguchi, Mamoru
    Kuwahara, Ken
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    CANCER MEDICINE, 2023, 12 (03): : 3176 - 3179
12345